A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges

Journal of the National Cancer Institute

Volumn 91, Issue 2, 1999, Pages 102-103

  Sausville, E A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN BCR ABL KINASE ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ENZYME REGULATION; HUMAN; HUMAN CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0033585485     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.2.102     Document Type: Editorial

References (17)